iclight,
Those of us around as long as me have likely cost averaged down. When Steven Giardino suggested I sell back when it was above $1 on its way down to $.14 back in 2016 I told him I had a different plan. By the way, he got burned on April 2015 puts when Mr. Woodford continued his funding of NWBO.
I could have made much more money selling at ~$12.54 because I knew that was not likely to last. Instead I chose to hang on through thick and thin just to be able to say that my confidence in this platform and company was unshakable and so patients and friends might know I was not investing just because of the money. I knew from the science the money would take care of itself over time and by cost averaging down and up into the lower $.30s I am up significantly with almost 12 years of accumulation. This along with the shares my kids and friends have represents something a little more than insignificant amount even with so many shares outstanding.
If you go back to some of my posts from years ago during the long price decline you will notice that I suggested the price could go as low as $.05 which fortunately the Sawston land purchase and subsequent sale prevented but I was prepared for. Obviously I had been sharing about the kind of attacks that you and others would end up being part of. In my Seeking Alpha postings I pointed out the DNDN type of attacks and price action that NWBO shareholders should expect which has happened and the rebound will happen too. Unlike DNDN the manufacturing processes for L and Direct have been just about fully validated and ready for prime time in multiple cancer indications and as SOC worldwide. This is going to be critically important for the sake of taking into account the pressure to grant tissue agnostic designation early on and moving past just Specials instead of waiting for years while patients die from treatable disease.
I also stated from the beginning that I would be in until the end because early research pointed to synergistic effect between intradermal and intratumoral administration of DCs and only NWBO was in process of developing both. This is the big threat that big pharma initially discounted, found out how wrong they were then realized they needed to buy time and figure out a way to bring down, work with or attempt to buy out NWBO.
The problem is that NWBO is tightly held by longs willing to hold for generational wealth and that is very frustrating to those who know they made a big mistake not getting in much earlier. The idea of combos is appealing but if there are only 15% of patients receiving benefit over and above L plus Poly-ICLC then use may eventually drop off so making as much as possible off of checkpoint inhibitors now seems a likely a top priority. Gee, I wonder if any of the attacks have anything to do with tag at?; ). Best wishes.
News 
Market Data 
Discover 
AI
